Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio

Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia that is characterized by a steadily progressive course and poor prognosis. The worsening pulmonary fibrosis resulting in honeycomb lungs accounts for the deterioration of clinical symptoms and functional...

Full description

Bibliographic Details
Main Authors: S. N. Avdeev, N. V. Trushenko
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-10-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/2682
_version_ 1797842073174409216
author S. N. Avdeev
N. V. Trushenko
author_facet S. N. Avdeev
N. V. Trushenko
author_sort S. N. Avdeev
collection DOAJ
description Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia that is characterized by a steadily progressive course and poor prognosis. The worsening pulmonary fibrosis resulting in honeycomb lungs accounts for the deterioration of clinical symptoms and functional status in patients with IPF. Today, the drugs with anti-fibrotic properties are recommend as a drug therapy for IPF. The article provides information on the efficacy and safety of this therapy as well as practical guidelines on the management of patients with IPF receiving such therapy.
first_indexed 2024-04-09T16:41:49Z
format Article
id doaj.art-ec8b66b2ca6d4cc2a8954eb23ad1f523
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:41:49Z
publishDate 2018-10-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-ec8b66b2ca6d4cc2a8954eb23ad1f5232023-04-23T06:56:40ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-10-0101513113610.21518/2079-701X-2018-15-131-1362634Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratioS. N. Avdeev0N. V. Trushenko1Sechenov First Moscow State Medical University of the Ministry of Health of RussiaResearch Institute of Pulmonology of the Federal Medical-Biological Agency of RussiaIdiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia that is characterized by a steadily progressive course and poor prognosis. The worsening pulmonary fibrosis resulting in honeycomb lungs accounts for the deterioration of clinical symptoms and functional status in patients with IPF. Today, the drugs with anti-fibrotic properties are recommend as a drug therapy for IPF. The article provides information on the efficacy and safety of this therapy as well as practical guidelines on the management of patients with IPF receiving such therapy.https://www.med-sovet.pro/jour/article/view/2682idiopathic pulmonary fibrosistreatmentantifibrotic therapypirfenidone
spellingShingle S. N. Avdeev
N. V. Trushenko
Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Медицинский совет
idiopathic pulmonary fibrosis
treatment
antifibrotic therapy
pirfenidone
title Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
title_full Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
title_fullStr Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
title_full_unstemmed Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
title_short Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
title_sort antifibrotic therapy of idiopathic pulmonary fibrosis efficiency safety ratio
topic idiopathic pulmonary fibrosis
treatment
antifibrotic therapy
pirfenidone
url https://www.med-sovet.pro/jour/article/view/2682
work_keys_str_mv AT snavdeev antifibrotictherapyofidiopathicpulmonaryfibrosisefficiencysafetyratio
AT nvtrushenko antifibrotictherapyofidiopathicpulmonaryfibrosisefficiencysafetyratio